Endocrine Interruption Does Not Impact Short-Term Disease in Breast Cancer
Patients with breast cancer who pause their endocrine therapy to try to get pregnant experienced...
Read More
Author: Rebecca Shover
MammaPrint Predicts Extended Endocrine Therapy Benefit
In addition to predicting the benefit of adjuvant chemotherapy in patients with early breast...
Read More
Dr. MedLaw Q&A: Patient Abandonment After Being Fired?
Q: I was just fired from my pulmonology group after a very bad fallout with the managing partner....
Read More
MagnetisMM-3 Trial: Elranatamab Promising for MM
Elranatamab displayed a manageable safety profile in patients with relapsed/refractory multiple...
Read More
MRD by qPCR Prognostic of Outcomes in Venetoclax-Treated, NPM1-Mutated AML
Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...
Read More
Excellent Results for Triplet Regimen in FLT3-Mutated AML
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Read More
CAR-Hematotox Score Predicts Toxicity, Infection & Clinical Outcomes in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read More
Deep & Durable Responses for Quadruple Therapy in Smouldering MM
The quadruple therapy of daratumumab, carfilzomib, lenalidomide, and dexamethasone was well...
Read More
Ibrutinib Delays Need for Next Treatment in Real-World First-Line CLL
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Read More
Test Your SOHO Knowledge!
A quiz based on the latest lung cancer news and studies from SOHO.
Read More
Test Your ASN Knowledge!
The ASN 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly.
Read More
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Read More
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
Read More
Ibrutinib Added to ASCT Improves Clinical Outcomes in Mantle Cell Lymphoma
In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...
Read More
How Physicians Can Adjust to Working in Toxic Environment
Despite the many years of schooling and post-graduate training undergone by physicians, it rarely...
Read More
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Read More
Efgartigimod Successful in Immune Thrombocytopenia
Efgartigimod significantly improved platelet counts in patients with primary immune...
Read More
Talquetamab Further Investigated in Heavily Pre-Treated MM After Promising Phase 2 Data
Talquetamab demonstrated a favorable safety profile and promising response rates in a heavily...
Read More
Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read More